{"transactions":[{"id":750011,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T22:05:52.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":7490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 2, 2026. Price not applicable."}],"balance_after":21040,"source":{"system":"sec-edgar","filing":"0001628280-26-040914","document":"wk-form4_1780610750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026040914/wk-form4_1780610750.xml","form_type":"4"}},{"id":785209,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-11T20:32:42.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1438,"price":177.62,"value":255417.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":2384,"source":{"system":"sec-edgar","filing":"0001100682-26-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000110068226000050/form4.xml","form_type":"4"}},{"id":1123401,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-04T20:42:38.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":2082,"price":135.04,"value":281153.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The stock options become exercisable upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":2082,"derivative":{"exercise_price":135.04,"exercise_date":"2026-06-02","expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":2082},"source":{"system":"sec-edgar","filing":"0001127602-25-016729","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760225016729/form4.xml","form_type":"4"}},{"id":1123400,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-04T20:42:38.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":946,"price":135.04,"value":127747.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 6/2/2026 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":946,"source":{"system":"sec-edgar","filing":"0001127602-25-016729","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760225016729/form4.xml","form_type":"4"}},{"id":1137823,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T20:56:05.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":6650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 20, 2025. Price not applicable."}],"balance_after":13550,"source":{"system":"sec-edgar","filing":"0001048477-25-000070","document":"wk-form4_1747947358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000070/wk-form4_1747947358.xml","form_type":"4"}},{"id":1504166,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-23T21:23:09.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":4720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 21, 2024. Price not applicable."}],"balance_after":6900,"source":{"system":"sec-edgar","filing":"0001048477-24-000100","document":"wk-form4_1716499371.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000100/wk-form4_1716499371.xml","form_type":"4"}},{"id":1650472,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":10.65,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1650471,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":922400,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.66,"expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":922400},"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1650470,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.32,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1650469,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":925000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":7.69,"expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":925000},"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1650468,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":196875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock (\"Stock Option\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":4.55,"expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":196875},"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1650467,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":140357,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU granted on or after the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was converted into a grant of restricted stock unit awards in respect of a number of shares of AbbVie common stock equal to the number of shares of Common Stock underlying such RSU as of immediately prior to the Effective Time multiplied by 0.18, and otherwise with the same terms and conditions that were applicable immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":140357},"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1650466,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":102466,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":102466},"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1650465,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-12T16:46:37.000Z","date":"2024-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":584397,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation (\"AbbVie\"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (\"Intermediate Sub\"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub (\"Purchaser\"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of common stock, par value $.01 per share, of the Issuer (the \"Common Stock\"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-014715","document":"tm245865-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000110465924014715/tm245865-13_4seq1.xml","form_type":"4"}},{"id":1657510,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-06T21:42:45.000Z","date":"2024-02-02","kind":"exercise","planned":true,"acquired":false,"shares":51234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were granted on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were granted on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":102466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":51234},"source":{"system":"sec-edgar","filing":"0001415889-24-002871","document":"form4-02072024_020237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002871/form4-02072024_020237.xml","form_type":"4"}},{"id":1657509,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-06T21:42:45.000Z","date":"2024-02-05","kind":"sale","planned":true,"acquired":false,"shares":20107,"price":29.28,"value":588732.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.25 to $29.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":584397,"source":{"system":"sec-edgar","filing":"0001415889-24-002871","document":"form4-02072024_020237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002871/form4-02072024_020237.xml","form_type":"4"}},{"id":1657508,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-06T21:42:45.000Z","date":"2024-02-02","kind":"exercise","planned":true,"acquired":true,"shares":51234,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":604504,"source":{"system":"sec-edgar","filing":"0001415889-24-002871","document":"form4-02072024_020237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002871/form4-02072024_020237.xml","form_type":"4"}},{"id":1659950,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2024-02-05T21:23:19.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":140357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":140357,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":140357},"source":{"system":"sec-edgar","filing":"0001415889-24-002759","document":"form4-02062024_020211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588924002759/form4-02062024_020211.xml","form_type":"4"}},{"id":1698925,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-28T18:13:03.000Z","date":"2023-12-27","kind":"grant","planned":false,"acquired":true,"shares":2180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on December 27, 2023. Price not applicable."}],"balance_after":2180,"source":{"system":"sec-edgar","filing":"0001048477-23-000072","document":"wk-form4_1703787170.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000072/wk-form4_1703787170.xml","form_type":"4"}},{"id":1815442,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":false,"shares":21978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":196875,"derivative":{"exercise_price":4.55,"exercise_date":"2021-02-07","expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":21978},"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815441,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":false,"shares":782240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable in three equal installments over three years starting on the first year anniversary of the grant."}],"balance_after":0,"derivative":{"exercise_price":5.25,"exercise_date":"2020-01-31","expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":782240},"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815440,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Exercisable in four equal installments over four years starting on the first year anniversary of the grant."}],"balance_after":0,"derivative":{"exercise_price":5.65,"exercise_date":"2017-05-16","expiration_date":"2026-05-16","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815439,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-03","kind":"exercise","planned":false,"acquired":false,"shares":186093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in installments upon the satisfaction of certain performance criteria."}],"balance_after":196875,"derivative":{"exercise_price":4.55,"exercise_date":"2022-11-14","expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":186093},"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815438,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-03","kind":"exercise","planned":false,"acquired":false,"shares":831147,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years."}],"balance_after":218853,"derivative":{"exercise_price":4.55,"exercise_date":"2021-02-07","expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":831147},"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815437,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-03","kind":"exercise","planned":false,"acquired":false,"shares":2760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable in three equal installments over three years starting on the first year anniversary of the grant."}],"balance_after":782240,"derivative":{"exercise_price":5.25,"exercise_date":"2020-01-31","expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":2760},"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815436,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-02","kind":"exercise","planned":false,"acquired":false,"shares":995157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in installments upon the satisfaction of certain performance criteria."}],"balance_after":382968,"derivative":{"exercise_price":4.55,"exercise_date":"2022-11-14","expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":995157},"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815435,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-04","kind":"sale","planned":false,"acquired":false,"shares":992397,"price":16.96,"value":16831053.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $17.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":553270,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815434,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":true,"shares":300000,"price":5.65,"value":1695000.0,"ownership":{"direct":true},"balance_after":1545667,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815433,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":true,"shares":21978,"price":4.55,"value":99999.9,"ownership":{"direct":true},"balance_after":1245667,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815432,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-04","kind":"exercise","planned":false,"acquired":true,"shares":782240,"price":5.25,"value":4106760.0,"ownership":{"direct":true},"balance_after":1223689,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815431,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-03","kind":"sale","planned":false,"acquired":false,"shares":1020000,"price":16.61,"value":16942200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":441449,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815430,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-03","kind":"exercise","planned":false,"acquired":true,"shares":1017240,"price":4.55,"value":4628442.0,"ownership":{"direct":true},"balance_after":1461449,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815429,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-03","kind":"exercise","planned":false,"acquired":true,"shares":2760,"price":5.25,"value":14490.0,"ownership":{"direct":true},"balance_after":444209,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815428,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-02","kind":"sale","planned":false,"acquired":false,"shares":8636,"price":18.15,"value":156743.4,"ownership":{"direct":true},"balance_after":441449,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815427,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-02","kind":"sale","planned":false,"acquired":false,"shares":986521,"price":17.45,"value":17214791.45,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.14 to $18.11, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges."}],"balance_after":450085,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1815426,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-04T19:32:15.000Z","date":"2023-08-02","kind":"exercise","planned":false,"acquired":true,"shares":995157,"price":4.55,"value":4527964.35,"ownership":{"direct":true},"balance_after":1436606,"source":{"system":"sec-edgar","filing":"0001415889-23-011881","document":"form4-08042023_110845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923011881/form4-08042023_110845.xml","form_type":"4"}},{"id":1838232,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-07-05T17:57:50.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":5241,"price":4.05,"value":21226.05,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2023 through June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023."}],"balance_after":441449,"source":{"system":"sec-edgar","filing":"0001415889-23-010830","document":"form4-07052023_090745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923010830/form4-07052023_090745.xml","form_type":"4"}},{"id":2029509,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-07T17:20:10.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":922400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":922400,"derivative":{"exercise_price":4.66,"expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":922400},"source":{"system":"sec-edgar","filing":"0001415889-23-002104","document":"form4-02072023_100202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923002104/form4-02072023_100202.xml","form_type":"4"}},{"id":2029508,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2023-02-07T17:20:10.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":153700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date."}],"balance_after":153700,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":153700},"source":{"system":"sec-edgar","filing":"0001415889-23-002104","document":"form4-02072023_100202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588923002104/form4-02072023_100202.xml","form_type":"4"}},{"id":2076352,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-27T17:16:52.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":787500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award."}],"balance_after":1181250,"derivative":{"exercise_price":4.55,"exercise_date":"2022-11-14","expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":787500},"source":{"system":"sec-edgar","filing":"0001415889-22-012993","document":"form4-12272022_101239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922012993/form4-12272022_101239.xml","form_type":"4"}},{"id":2076351,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-27T17:16:52.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":393750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award."}],"balance_after":393750,"derivative":{"exercise_price":4.55,"exercise_date":"2022-05-20","expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":393750},"source":{"system":"sec-edgar","filing":"0001415889-22-012993","document":"form4-12272022_101239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922012993/form4-12272022_101239.xml","form_type":"4"}},{"id":2111548,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T02:13:44.000Z","date":"2022-11-16","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.38,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-22-036305","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000089924322036305/doc4.xml","form_type":"4"}},{"id":2111547,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-18T02:13:44.000Z","date":"2022-11-16","kind":"disposition_to_issuer","acquired":false,"shares":2921,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the \"Merger Agreement\"), by and among LogicBio Therapeutics, Inc. (the \"Company\"), Alexion Pharmaceuticals, Inc. (\"Parent\") and Camelot Merger Sub, Inc. (\"Merger Sub\"), on November 16, 2022 (the \"Effective Time\"), Merger Sub merged with and into the Company (the \"Merger\"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-036305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000089924322036305/doc4.xml","form_type":"4"}},{"id":2215874,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-07-05T16:28:16.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":3342,"price":3.825,"value":12783.15,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2022 through June 30, 2022"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2022"}],"balance_after":436208,"source":{"system":"sec-edgar","filing":"0001415889-22-007327","document":"form4-07052022_010747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000141588922007327/form4-07052022_010747.xml","form_type":"4"}},{"id":2224906,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T12:05:31.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The options were granted by LogicBio Therapeutics, Inc. (the \"Company\") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.38,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-038235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000120919122038235/doc4.xml","form_type":"4"}},{"id":2409134,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-08T17:34:17.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":1100000,"price":5.32,"value":5852000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant."}],"balance_after":1100000,"derivative":{"exercise_price":5.32,"exercise_date":"2023-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0001179110-22-000928","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911022000928/edgar.xml","form_type":"4"}},{"id":2646302,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-07-02T16:21:15.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":3849,"price":5.52,"value":21246.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2021 through June 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021."}],"balance_after":432866,"source":{"system":"sec-edgar","filing":"0001179110-21-007317","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021007317/edgar.xml","form_type":"4"}},{"id":2669671,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T00:01:06.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan as provided under the Company's compensation policy for non-employee directors. All of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2022 annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer through the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":4.59,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-040430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000120919121040430/doc4.xml","form_type":"4"}},{"id":2873085,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-09T20:13:28.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":925000,"price":7.69,"value":7113250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the options are exercisable on the first year anniversary of the grant and the balance is exercisable in twelve equal installments of 6.25%, quarterly over the following three years starting one quarter after the first year anniversary."}],"balance_after":925000,"derivative":{"exercise_price":7.69,"exercise_date":"2022-02-05","expiration_date":"2031-02-05","underlying":"Common Stock","underlying_shares":925000},"source":{"system":"sec-edgar","filing":"0001179110-21-001497","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021001497/edgar.xml","form_type":"4"}},{"id":2873084,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-09T20:13:28.000Z","date":"2020-12-22","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift of common stock donated to charitable funds."}],"balance_after":429017,"source":{"system":"sec-edgar","filing":"0001179110-21-001497","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911021001497/edgar.xml","form_type":"4"}},{"id":2924944,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-01-05T00:00:12.000Z","date":"2021-01-01","kind":"exercise","acquired":false,"shares":2921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the \"Company\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2921},"source":{"system":"sec-edgar","filing":"0001209191-21-000518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000120919121000518/doc4.xml","form_type":"4"}},{"id":2924943,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T00:00:12.000Z","date":"2021-01-01","kind":"exercise","acquired":true,"shares":2921,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the \"Company\")."}],"balance_after":2921,"source":{"system":"sec-edgar","filing":"0001209191-21-000518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000120919121000518/doc4.xml","form_type":"4"}},{"id":3093814,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-07-02T08:41:39.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":5241,"price":3.91,"value":20492.31,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from January 1, 2020 through June 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2020."}],"balance_after":439017,"source":{"system":"sec-edgar","filing":"0001179110-20-007819","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020007819/edgar.xml","form_type":"4"}},{"id":3101727,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-24T00:00:23.000Z","date":"2020-06-19","kind":"grant","acquired":true,"shares":2921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of LogicBio Therapeutics Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan."}],"balance_after":2921,"derivative":{"underlying":"Common Stock","underlying_shares":2921},"source":{"system":"sec-edgar","filing":"0001209191-20-038664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000120919120038664/doc4.xml","form_type":"4"}},{"id":3115885,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-06-09T20:17:02.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"Stock Option\"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":20100,"derivative":{"exercise_price":11.96,"exercise_date":"2021-06-05","expiration_date":"2030-06-05","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001562180-20-004355","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218020004355/primarydocument.xml","form_type":"4"}},{"id":3115884,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T20:17:02.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"RSUs\"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":31143,"source":{"system":"sec-edgar","filing":"0001562180-20-004355","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218020004355/primarydocument.xml","form_type":"4"}},{"id":3200216,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-20T00:00:15.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, March 17, 2020."}],"balance_after":20000,"derivative":{"exercise_price":5.34,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-020355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586965/000120919120020355/doc4.xml","form_type":"4"}},{"id":3250760,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-02-25T08:38:19.000Z","date":"2020-02-24","kind":"sale","acquired":false,"shares":55222,"price":4.99,"value":275557.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Weighted average price of shares sold."}],"balance_after":433776,"source":{"system":"sec-edgar","filing":"0001179110-20-002186","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020002186/edgar.xml","form_type":"4"}},{"id":3280581,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-11T09:26:29.000Z","date":"2020-02-07","kind":"grant","acquired":true,"shares":1050000,"price":4.55,"value":4777500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options are exercisable on the first year anniversary of the grant and the balance is exercisable in twelve equal installments of 6.25%, quarterly over the following three years starting one quarter after the first year anniversary."}],"balance_after":1050000,"derivative":{"exercise_price":4.55,"exercise_date":"2021-02-07","expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":1050000},"source":{"system":"sec-edgar","filing":"0001179110-20-001427","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911020001427/edgar.xml","form_type":"4"}},{"id":3472981,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-07-02T13:39:47.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":5230,"price":1.84,"value":9623.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2019."}],"balance_after":488998,"source":{"system":"sec-edgar","filing":"0001179110-19-008316","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911019008316/edgar.xml","form_type":"4"}},{"id":3495374,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-06-10T20:04:05.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"Stock Option\").  100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":20100,"derivative":{"exercise_price":4.23,"exercise_date":"2020-06-06","expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001562180-19-003434","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019003434/primarydocument.xml","form_type":"4"}},{"id":3495373,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-10T20:04:05.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the \"RSUs\").  100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":17443,"source":{"system":"sec-edgar","filing":"0001562180-19-003434","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000156218019003434/primarydocument.xml","form_type":"4"}},{"id":3637080,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-02-25T10:11:40.000Z","date":"2018-02-22","kind":"sale","acquired":false,"shares":51070,"price":5.6,"value":285992.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Weighted average price of shares sold."}],"balance_after":483768,"source":{"system":"sec-edgar","filing":"0001179110-19-002471","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911019002471/edgar.xml","form_type":"4"}},{"id":3678474,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-04T16:36:05.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":785000,"price":5.25,"value":4121250.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable in three equal installments over three years starting on the first year anniversary of the grant."}],"balance_after":785000,"derivative":{"exercise_price":5.25,"exercise_date":"2020-01-31","expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":785000},"source":{"system":"sec-edgar","filing":"0001179110-19-001229","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911019001229/edgar.xml","form_type":"4"}},{"id":3706096,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-01-04T11:09:06.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":2455,"price":4.08,"value":10016.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from July 1, 2018 through December 31, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2018."}],"balance_after":534838,"source":{"system":"sec-edgar","filing":"0001179110-19-000357","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911019000357/edgar.xml","form_type":"4"}},{"id":3731830,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:39:35.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":8.94,"expiration_date":"2028-12-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-030947","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924318030947/doc4.xml","form_type":"4"}},{"id":3731829,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:39:35.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":11229,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a \"Keryx Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an \"Issuer Option\") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and currently exercisable."}],"balance_after":11229,"derivative":{"exercise_price":10.05,"expiration_date":"2028-06-30","underlying":"Common Stock","underlying_shares":11229},"source":{"system":"sec-edgar","filing":"0000899243-18-030947","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924318030947/doc4.xml","form_type":"4"}},{"id":3731828,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2018-12-13T23:39:35.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":18716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a \"Keryx Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an \"Issuer Option\") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and currently exercisable."}],"balance_after":18716,"derivative":{"exercise_price":19.56,"expiration_date":"2027-09-11","underlying":"Common Stock","underlying_shares":18716},"source":{"system":"sec-edgar","filing":"0000899243-18-030947","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924318030947/doc4.xml","form_type":"4"}},{"id":3731827,"issuer":{"id":6105,"kind":"organization","name":"Akebia Therapeutics, Inc."},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T23:39:35.000Z","date":"2018-12-12","kind":"grant","acquired":true,"shares":3743,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the \"Merger Agreement\"), each share of common stock of Keryx Biopharmaceuticals, Inc. (\"Keryx\") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the \"Effective Time\") was automatically converted into 0.37433 shares of the Issuer's common stock (the \"Exchange Multiplier\")."}],"balance_after":3743,"source":{"system":"sec-edgar","filing":"0000899243-18-030947","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517022/000089924318030947/doc4.xml","form_type":"4"}},{"id":3733008,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-12-13T16:39:17.000Z","date":"2018-12-12","kind":"disposition_to_issuer","acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-18-030892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924318030892/doc4.xml","form_type":"4"}},{"id":3733007,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T16:39:17.000Z","date":"2018-12-12","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. (\"Keryx\"), Akebia Therapeutics, Inc. (\"Akebia\") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the \"Merger Agreement\"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the \"Exchange Ratio\"), with fractional shares being paid in cash as provided in the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 10,000 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. (\"Keryx\"), Akebia Therapeutics, Inc. (\"Akebia\") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the \"Merger Agreement\"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the \"Exchange Ratio\"), with fractional shares being paid in cash as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 10,000 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-030892","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924318030892/doc4.xml","form_type":"4"}},{"id":3868899,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-07-12T18:00:40.000Z","date":"2018-06-30","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The 30,000 stock options vest as to one-third on each of June 30, 2019, June 30, 2020 and June 30, 2021."}],"balance_after":30000,"derivative":{"exercise_price":3.76,"exercise_date":"2019-06-30","expiration_date":"2028-06-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001114220-18-000077","document":"wf-form4_153143282475924.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000077/wf-form4_153143282475924.xml","form_type":"4"}},{"id":3868898,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-12T18:00:40.000Z","date":"2018-06-30","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 30, 2019, June 30, 2020 and June 30, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,000 shares of restricted stock."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001114220-18-000077","document":"wf-form4_153143282475924.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000077/wf-form4_153143282475924.xml","form_type":"4"}},{"id":4038201,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-23T11:46:41.000Z","date":"2018-02-21","kind":"sale","acquired":false,"shares":67717,"price":10.87,"value":736083.79,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Weighted average price of shares sold."}],"balance_after":532383,"source":{"system":"sec-edgar","filing":"0001179110-18-002677","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911018002677/edgar.xml","form_type":"4"}},{"id":4049534,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-20T16:02:24.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":1100000,"price":10.65,"value":11715000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable in three equal installments over three years starting on the first year anniversary of the grant."}],"balance_after":1100000,"derivative":{"exercise_price":10.65,"exercise_date":"2019-02-15","expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0001179110-18-002364","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911018002364/edgar.xml","form_type":"4"}},{"id":4210797,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2017-09-13T20:57:34.000Z","date":"2017-09-11","kind":"grant","acquired":true,"shares":50000,"price":7.32,"value":366000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The 50,000 stock options vest as follows: 16,667 on September 11, 2018; 16,667 on September 11, 2019; 16,666 on September 11, 2020."}],"balance_after":50000,"derivative":{"exercise_price":7.32,"exercise_date":"2018-09-11","expiration_date":"2027-09-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001114220-17-000028","document":"wf-form4_150535063941262.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422017000028/wf-form4_150535063941262.xml","form_type":"4"}},{"id":4333232,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-04T15:58:14.000Z","date":"2017-05-02","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 2, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":25000,"derivative":{"exercise_price":4.73,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-029929","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919117029929/doc4.xml","form_type":"4"}},{"id":4429162,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-02-23T15:21:48.000Z","date":"2017-02-21","kind":"grant","acquired":true,"shares":500000,"price":2.47,"value":1235000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are restricted stock which vest annually in three equal installments commencing on February 21, 2018."}],"balance_after":600100,"source":{"system":"sec-edgar","filing":"0001179110-17-003021","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911017003021/edgar.xml","form_type":"4"}},{"id":4562967,"issuer":{"id":94428,"kind":"organization","name":"ImmunoGen, Inc.","symbol":"IMGN"},"owners":[{"id":41447,"kind":"person","name":"Enyedy Mark J","position":1,"cik":"0001586965","reported_name":"Enyedy Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2016-11-09T13:34:29.000Z","date":"2016-11-08","kind":"purchase","acquired":true,"shares":25000,"price":1.8295,"value":45737.5,"ownership":{"direct":true},"balance_after":100100,"source":{"system":"sec-edgar","filing":"0001179110-16-031371","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/855654/000117911016031371/edgar.xml","form_type":"4"}}]}